|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Cost of revenues | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| General and administrative, including stock-based compensation of $981 thousand and $1,254 thousand, for the years ended December 31, 2025 and 2024, respectively | |||||
| Impairment of intangible assets | |||||
| Excess fair value of equity issuance over assets received | |||||
| Research and development, including stock-based compensation of $0 thousand and $138 thousand, for the years ended December 31, 2025 and 2024, respectively | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income (expenses) | |||||
| Interest expense | |||||
| Interest expense | |||||
| Change in fair value of derivative liability | |||||
| Gain on debt extinguishment | |||||
| Other income (expenses) | |||||
| Loss on change in fair value of contingent consideration | |||||
| Debt discount amortization | |||||
| Other income | |||||
| Total other expenses | |||||
| Loss before provision for income taxes | |||||
| Provision for income taxes | |||||
| Net loss | |||||
| Deemed dividend related to warrant resets | |||||
| Net loss attributable to common stockholders | |||||
| Basic net loss per common share | |||||
| Diluted net loss per common share | |||||
| Weighted-average number of shares used basic per share amounts | |||||
| Weighted-average number of shares used diluted per share amounts | |||||
Loading...